Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9350384 | 0.89 | MEN1 (0.41) | ENPP2TSHR | |
| SCHEMBL138492 | 0.81 | ACHE (0.42) | TSHR | |
| SCHEMBL123838 | 0.81 | TSHR (0.61) | ENPP2PRSS1PRSS2PRSS3TSHR | |
| SCHEMBL13001900 | 0.78 | ENPP2 (0.53) | ENPP2FFAR1 | |
| SCHEMBL26920214 | 0.78 | TSHR (0.42) | ENPP2TSHR | |
| SCHEMBL357440 | 0.78 | ENPP2 (0.54) | ENPP2 | |
| SCHEMBL4374157 | 0.78 | ENPP2 (0.58) | ENPP2PRSS1PRSS2PRSS3TSHR | |
| Hydrochloric Acid SCHEMBL14334287 | 0.78 | ENPP2 (0.58) | ENPP2PRSS1PRSS2PRSS3TSHR | |
| SCHEMBL10546841 | 0.77 | CALM1 (0.50) | PRSS1PRSS2PRSS3TSHRACMSD | |
| SCHEMBL3694910 | 0.77 | TSHR (0.43) | PRSS1PRSS2PRSS3TSHRCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0584223-B1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMA (US) | 1999-08-11 | — | — | EP | claimed |
| EP-0789512-B1 | MIXTURES AND AGENTS SUITABLE FOR COMBATTING HYLOTRUPES BAJULUS AND PYRRHIDIUM SANGUINEUM | BASF AG (DE) | 1999-01-07 | — | — | EP | claimed |
| US-20250339406-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-11-06 | — | — | US | disclosed |
| US-12364688-B2 | NSD family inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-07-22 | — | — | US | disclosed |
| US-20230046569-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-02-16 | — | — | US | disclosed |
| US-20230046569-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-02-16 | — | — | US | disclosed |
| US-11324729-B2 | NSD family inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-05-10 | — | — | US | disclosed |
| US-11324729-B2 | NSD family inhibitors and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-05-10 | — | — | US | disclosed |
| CN-112040947-A | NSD family inhibitors and methods of treatment therewith | 密歇根大学董事会 | 2020-12-04 | — | — | CN | disclosed |
| EP-3720439-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | The Regents Of The University Of Michigan (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20190183865-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-06-20 | — | — | US | disclosed |
| EP-1203760-B1 | Method for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-6706910-B2 | BY TRANSESTERIFICATION OF A CYCLOPROPANECARBOXYLATE AND A MONOHYDROXY COMPOUND IN THE PRESENCE OF A LITHIUM ALKOXIDE OR LITHIUM ARYLOXIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-03-16 | — | — | US | disclosed |
| US-6531626-B1 | Transesterification in the presence of a samarium alkoxide | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-03-11 | — | — | US | disclosed |
| EP-0992479-B1 | Method for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL CO (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-6441220-B1 | ESTERIFICATION WITH ALCOHOL IN PRESENCE OF BASIC CATALYSTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-08-27 | — | — | US | disclosed |
| EP-1203760-A1 | Method for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-08 | — | — | EP | disclosed |
| US-20020052525-A1 | Method for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-02 | — | — | US | disclosed |
| EP-1061065-A2 | Methods for producing cyclopropane carboxylates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-20 | — | — | EP | disclosed |
| EP-0992479-A1 | Method for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12364688-B2 | NSD family inhibitors and methods of treatment therewith | NSD3, NSD2, NSD1 | ENPP2 2510/4885PRSS1 109/4885PRSS2 855/4885 |
| US-20230046569-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | NSD3, NSD2, NSD1 | ENPP2 2510/4885PRSS1 109/4885PRSS2 855/4885 |
| US-20020052525-A1 | Method for producing cyclopropanecarboxylates | CYP8B1, SRD5A2, CYP21A2 | ENPP2 3485/4885PRSS1 4608/4885PRSS2 4336/4885 |
| US-20250339406-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | NSD3, NSD2, NSD1 | ENPP2 2510/4885PRSS1 109/4885PRSS2 855/4885 |
| US-11324729-B2 | NSD family inhibitors and methods of treatment therewith | NSD3, NSD2, NSD1 | ENPP2 2510/4885PRSS1 109/4885PRSS2 855/4885 |
| US-20190183865-A1 | NSD FAMILY INHIBITORS AND METHODS OF TREATMENT THEREWITH | NSD3, NSD2, NSD1 | ENPP2 2510/4885PRSS1 109/4885PRSS2 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.